Hepatitis B Treatment in India and UAE | Complete Patient Guide

• Patients with confirmed chronic HBV infection (HBsAg-positive for >6 months)

• HBeAg-positive or HBeAg-negative chronic hepatitis B with HBV DNA >2,000 IU/mL AND ALT >1× ULN

• Patients with HBV DNA >20,000 IU/mL regardless of ALT if liver biopsy or FibroScan confirms ≥F2 fibrosis or necroinflammatory activity ≥A2

• Patients with compensated or decompensated cirrhosis secondary to HBV (any detectable HBV DNA level warrants treatment)

• HBV-related hepatocellular carcinoma (HCC) requiring antiviral suppression alongside oncological treatment (TACE, SBRT, sorafenib/lenvatinib)

• Patients with HBV reactivation in the context of immunosuppressive therapy (chemotherapy, biologics, corticosteroids)

• Liver transplant candidates with HBV-related end-stage liver disease

• Co-infected patients (HBV/HIV, HBV/HDV) requiring specialised combination regimens

Required Diagnostic Workup Before Treatment Initiation:

• HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc (IgM and IgG) serology panel

• Quantitative HBV DNA (PCR, IU/mL) — baseline viral load

• Quantitative HBsAg (qHBsAg, IU/mL) — predictive of treatment response

• Liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin, PT/INR)

• Complete blood count, renal function panel (eGFR — critical before TDF selection)

• FibroScan transient elastography (LSM in kPa) and/or FIB-4 index calculation

• Liver biopsy (METAVIR scoring) if non-invasive tests are inconclusive

• Abdominal ultrasound with Doppler (hepatosplenomegaly, portal hypertension assessment)

• AFP (alpha-fetoprotein) for HCC surveillance

• Hepatitis C (anti-HCV), HIV, and HDV (anti-HDV) co-infection screening

• MELD score calculation for cirrhotic/transplant candidates

Contraindications / Special Cautions:

• PEG-IFN is contraindicated in decompensated cirrhosis, autoimmune hepatitis, severe psychiatric illness, pregnancy, and uncontrolled thyroid disease

• TDF requires dose adjustment in patients with eGFR <50 mL/min; TAF is preferred in renal impairment

• Liver transplantation is contraindicated in active extrahepatic malignancy, uncontrolled systemic infection, severe cardiopulmonary disease, or ongoing substance abuse

ANTIVIRAL PHARMACOTHERAPY (First-Line, Non-Surgical)

Nucleos(t)ide Analogues (NUCs):

• Tenofovir Alafenamide (TAF, 25 mg/day): The current preferred first-line agent for most patients. TAF delivers tenofovir to hepatocytes via hepatic first-pass metabolism at 1/10th the plasma concentration of TDF, resulting in superior renal and bone safety profiles with equivalent antiviral potency. Resistance rate: <1% at 3 years.

• Tenofovir Disoproxil Fumarate (TDF, 300 mg/day): Highly effective, low-cost generic option widely used in India and the UAE. Preferred in pregnancy. Monitor eGFR and bone mineral density during long-term use.

• Entecavir (ETV, 0.5 mg/day; 1 mg/day in lamivudine-experienced patients): High barrier to resistance. Preferred in patients with renal insufficiency relative to TDF.

• Lamivudine and Adefovir are now largely obsolete as monotherapy due to high resistance rates and should not be used as first-line agents.

Pegylated Interferon Alfa-2a (PEG-IFN-α2a):

• 180 mcg subcutaneous injection weekly for 48 weeks.

• Achieves HBeAg seroconversion in ~30% and HBsAg loss (functional cure) in 3–7% of HBeAg-positive patients at week 48, rising to 11% at 5-year follow-up.

• Optimal candidates: Young age, high ALT (>5× ULN), low HBV DNA (<2×10^8 IU/mL), HBV genotype A or B, qHBsAg <20,000 IU/mL at baseline (the TREAT-B stopping rule).

• Side effects require active monitoring: flu-like syndrome, cytopenias, neuropsychiatric effects, thyroid dysfunction.

Combination and Sequential Strategies:

• PEG-IFN + NUC add-on or switch strategies are used in select patients to enhance HBsAg loss rates (ARES, OSST, New Switch trials protocols).

• HBV/HDV co-infected patients: Bulevirtide (Hepcludex) — an entry inhibitor — is the first approved therapy for chronic HDV infection and is available in specialist centres.

ADVANCED & INVESTIGATIONAL THERAPIES (Available at Tertiary Centres in India and UAE):

• Capsid Assembly Modulators (CAMs): JNJ-56136379 (Morphothiadin) and others in Phase 3 trials — disrupt HBV pregenomic RNA encapsidation and cccDNA production.

• RNA Interference (RNAi) Agents: Vir-2218, JNJ-3989 (siRNA) and GSK3228836 (ASO) reduce HBsAg levels by >90% and are being evaluated in combination with NUCs for functional cure.

• Immune Modulators: Therapeutic HBV vaccines, TLR7/8 agonists, PD-1/PD-L1 checkpoint inhibitors being trialled to restore HBV-specific T-cell immunity.

• Clinical trial access is available through AIIMS New Delhi, Tata Memorial Centre Mumbai, and Cleveland Clinic Abu Dhabi for eligible patients.

SURGICAL AND INTERVENTIONAL OPTIONS:

Liver Transplantation (Orthotopic Liver Transplantation — OLT):

• Indicated for HBV-related decompensated cirrhosis (Child-Pugh B/C, MELD score ≥15) or early-stage HCC within Milan criteria (single lesion ≤5 cm or up to 3 lesions ≤3 cm, no vascular invasion, no extrahepatic spread).

• Technique: Standard orthotopic transplantation with piggyback hepatic vein anastomosis or caval replacement. Living donor liver transplantation (LDLT) is a major strength of Indian centres (right lobe LDLT, volume-measured graft-to-recipient weight ratio >0.8%).

• Post-transplant HBV prophylaxis: Hepatitis B immunoglobulin (HBIG) in combination with NUC therapy (typically TDF or ETV) to prevent HBV recurrence — recurrence rates <5% with modern protocols.

• 5-year patient survival post-OLT: 80–90% in high-volume centres.

HCC-Directed Interventional Procedures (for HBV-related liver cancer):

• Transarterial Chemoembolisation (TACE): For intermediate-stage HCC (BCLC-B); drug-eluting bead TACE (DEB-TACE) offers reduced systemic toxicity vs conventional TACE.

• Transarterial Radioembolisation (TARE / SIRT): Yttrium-90 microsphere therapy for HCC with or without portal vein involvement.

• Stereotactic Body Radiotherapy (SBRT): Increasingly used as bridge-to-transplant or definitive therapy for HCC ≤5 cm.

• Radiofrequency Ablation (RFA) / Microwave Ablation (MWA): For early-stage HCC (BCLC-A) ≤3 cm; laparoscopic or percutaneous ultrasound/CT-guided.

• Systemic oncological therapy: Atezolizumab + Bevacizumab (IMbrave150 regimen) as first-line for advanced HCC; sorafenib and lenvatinib as alternative first-line; cabozantinib, regorafenib as second-line.

PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure)

• Share all existing medical records with GAF Healthcare: prior HBV serology, HBV DNA PCR results, liver imaging, biopsy reports, and current medications.

• GAF Healthcare's medical team reviews records and matches patient with the appropriate specialist (hepatologist, transplant surgeon, or interventional oncologist).

• Preliminary treatment plan and cost estimate issued within 48–72 hours.

• E-Medical visa application support initiated for India (Indian e-Medical Visa — typically granted within 3–5 business days); visa-on-arrival or prior visa-free entry facilitated for UAE.

• Travel insurance with medical coverage confirmation advised.

PHASE 2 — ARRIVAL & DIAGNOSTIC WORKUP (Days 1–3 in country)

• GAF Healthcare representative meets patient at airport with wheelchair assistance if required; transfer to partner hospital or serviced accommodation.

• Comprehensive hepatology workup conducted: quantitative HBV DNA, qHBsAg, complete liver function panel, FibroScan elastography (result available same day), abdominal ultrasound with Doppler, AFP.

• Specialist consultation (Day 1–2): Hepatologist reviews all investigations and confirms diagnosis, disease stage (METAVIR fibrosis, Child-Pugh, MELD scores for cirrhotic patients), and individualised treatment plan.

• Multidisciplinary team (MDT) review if HCC or transplant workup required — includes hepatology, transplant surgery, interventional radiology, oncology.

PHASE 3A — ANTIVIRAL TREATMENT INITIATION (Outpatient, Days 3–7)

• For patients managed with NUC monotherapy (the majority): Medication prescribed and dispensed; patient educated on adherence, monitoring parameters, and potential side effects.

• Baseline renal function and bone density tests completed before TDF initiation.

• For PEG-IFN candidates: First injection administered under supervision with 30-minute observation; self-injection training provided.

• Follow-up appointment scheduled at week 4 (HBV DNA, ALT, CBC) — can be conducted remotely via GAF Healthcare's telemedicine platform.

PHASE 3B — LIVER TRANSPLANTATION (Inpatient, for surgical candidates)

• Pre-operative assessment: Cardiopulmonary evaluation (echocardiography, right heart catheterisation if indicated), anaesthesia fitness, cross-sectional imaging (triphasic CT liver volumetry or MRI), MELD recalculation.

• Living donor evaluation (for LDLT): CT volumetry, MRI biliary anatomy, cardiac and psychological clearance of donor.

• Surgery: OLT procedure duration 6–12 hours; conducted under general anaesthesia. ICU admission post-operatively (Days 1–5). Extubation target: 12–24 hours.

• Hospital ward stay: Days 5–14 post-surgery (uncomplicated cases).

• Post-transplant protocol: HBIG IV infusion (Day 0 and daily for 7 days), followed by long-term NUC + low-dose HBIG or NUC monotherapy with HBsAg monitoring.

• Rejection surveillance: Tacrolimus trough levels monitored daily initially; target 8–12 ng/mL in first month.

PHASE 4 — POST-TREATMENT RECOVERY & DISCHARGE PLANNING

• For antiviral therapy patients: Clinically stable patients may typically return home within 1–2 weeks after confirming treatment tolerability; follow-up HBV DNA at week 4 via telemedicine.

• For liver transplant recipients: Minimum 6-week in-country stay required post-surgery. Week 4–6 milestones: ambulation without assistance, oral immunosuppression optimised, first biopsy-proven rejection episode (if any) treated. Clearance for international flight only after hepatologist and transplant surgeon written sign-off.

• GAF Healthcare provides detailed discharge summary, all histopathology and radiology reports in English (and local language if required), medication reconciliation list, and first follow-up telemedicine appointment scheduling.

• Long-term follow-up: HBV DNA and ALT monitoring every 3–6 months indefinitely; HCC surveillance ultrasound + AFP every 6 months for cirrhotic patients and transplant recipients.